Assembly Biosciences
11711 North Meridian Street
Suite 310
Indianapolis
Indiana
46032
United States
Tel: 855.971.4467
Website: http://www.assemblybio.com/
Email: info@assemblybio.com
About Assembly Biosciences
Assembly Biosciences, Inc. is a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome. The HBV program is focused on advancing a new class of potent, oral core inhibitors that have the potential to increase cure rates for chronically infected patients. The microbiome program is developing novel oral live microbial biotherapeutic candidates with Assembly’s fully integrated platform, including a robust process for strain identification and selection, GMP banking and production, and targeted delivery to the lower gastrointestinal tract with the GEMICEL® technology. For more information, visit assemblybio.com.
Stock Exchange: NASDAQ
Stock Symbol: ASMB
R & D Main Facility:
Assembly Biosciences
331 Oyster Point Blvd.
South San Francisco, CA 94080
132 articles about Assembly Biosciences
-
Nobel Laureate Dr. Michael Houghton Appointed to Assembly Biosciences Board of Directors
7/20/2021
Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus, announced that Sir Michael Houghton, PhD, has been appointed to the company’s board of directors.
-
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 02, 2021
7/2/2021
Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus, announced grants of stock options to three new employees to purchase an aggregate of 21,520 shares of the Company’s common stock with an exercise price of $3.82 per share, the closing price of Assembly Bio’s common stock on July 1, 2021.
-
Assembly Biosciences Presents Data from HBV Core Inhibitor Programs at the International Liver Congress™ EASL 2021
6/23/2021
Assembly Biosciences, Inc. (Nasdaq: ASMB), today announced data from its three clinical-stage core inhibitor programs, vebicorvir (VBR or ABI-H0731), ABI-H2158 (2158), and ABI-H3733 (3733), in an oral presentation and two poster presentations during the International Liver Congress™ 2021, the Annual Meeting of the European Association for the Study of the Liver (EASL),
-
Assembly Biosciences to Present Data from HBV Core Inhibitor Programs at The International Liver Congress™ EASL 2021
6/9/2021
Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced that three abstracts have been accepted for presentation during the International Liver Congress™ 2021, the Annual Meeting of the European Association for the Study of the Liver (EASL) taking place virtually June 23-26, 2021.
-
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 04, 2021
6/4/2021
Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus, announced grants of stock options to six new employees to purchase an aggregate of 106,520 shares of the Company’s common stock with an exercise price of $4.03 per share, the closing price of Assembly Bio’s common stock on June 1, 2021.
-
Dr. Lisa Johnson-Pratt Joins Assembly Biosciences Board of Directors
5/24/2021
Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus, announced that Lisa Johnson-Pratt, M.D., has joined the company’s board of directors.
-
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 07, 2021
5/7/2021
Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus, announced grants of stock options to three new employees to purchase an aggregate of 25,000 shares of the Company’s common stock with an exercise price of $4.16 per share, the closing price of Assembly Bio’s common stock on May 3, 2021.
-
Assembly Biosciences Reports First Quarter 2021 Financial Results and Recent Updates
5/6/2021
Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus, reported financial results and recent updates for the first quarter ended March 31, 2021.
-
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Mar 05, 2021
3/5/2021
Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus, announced grants of stock options to three new employees to purchase an aggregate of 26,000 shares of the Company’s common stock with an exercise price of $5.05 per share, the closing price of Assembly Bio’s common stock on March 1, 2021.
-
Assembly Biosciences and Arbutus Biopharma Initiate Phase 2 Clinical Trial of Triple Combination Therapy for the Treatment of Chronic Hepatitis B Virus
2/26/2021
Assembly Biosciences, Inc. (Nasdaq: ASMB) and Arbutus Biopharma Corporation (Nasdaq: ABUS) today announced the initiation of a Phase 2 clinical trial of Assembly Bio’s investigational hepatitis B virus (HBV) core inhibitor candidate
-
Assembly Biosciences Updates Pipeline Strategy, Focusing on Finite and Curative Therapies for Chronic Hepatitis B Virus Infection
2/25/2021
Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced that it is foregoing its plans to initiate Phase 3 registrational studies of vebicorvir
-
Assembly Biosciences Reports Fourth Quarter and Year End 2020 Financial Results and Recent Highlights
2/25/2021
Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus, reported financial results and recent highlights for the fourth quarter and year ended December 31, 2020.
-
Assembly Bio Announces Upcoming Investor Events
2/19/2021
Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced two upcoming investor events:
-
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb 05, 2021
2/5/2021
Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus, announced grants of stock options to three new employees to purchase an aggregate of 38,000 shares of the Company’s common stock with an exercise price of $5.79 per share, the closing price of Assembly Bio’s common stock on February 1, 2021.
-
Assembly Biosciences to Wind-Down Microbiome ProgramCompany will prioritize resources to focus on advancement of novel HBV therapeutic portfolio
12/8/2020
Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced that it will wind-down its microbiome program, enabling the company to prioritize resources and focus on the advancement of its pipeline of novel core inhibitors for chronic HBV.
-
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Dec 04, 2020
12/4/2020
Assembly Biosciences, Inc. announced grants of stock options to three new employees to purchase an aggregate of 14,520 shares of the Company’s common stock with an exercise price of $5.66 per share, the closing price of Assembly Bio’s common stock on December 1, 2020.
-
Assembly Biosciences Appoints Nicole S. White, PhD, as Senior Vice President of Pharmaceutical Development and Manufacturing
11/17/2020
Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced the appointment of Nicole S. White, PhD, as Senior Vice President of Pharmaceutical Development and Manufacturing
-
Assembly Biosciences and Door Pharmaceuticals Sign Collaboration and Option Agreement to Develop a Novel Class of HBV Core Protein Modulators
11/16/2020
Assembly Biosciences, Inc. (Nasdaq: ASMB) and Door Pharmaceuticals, LLC today announced that the companies have signed an exclusive, two-year collaboration and option agreement focused on the development of a novel class of hepatitis B virus (HBV) core protein modulators. Door Pharmaceuticals’ innovative discovery platform targets functions of core protein distinct from viral assembly and that have the potential to interfere with v
-
Assembly Biosciences Presents Data from HBV Core Inhibitor Programs in Poster Sessions at the 2020 AASLD The Liver Meeting Digital Experience™
11/13/2020
Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that data from its HBV core inhibitor programs and related research will be highlighted during four poster sessions – including two late-breakers – at the 2020 American Association for the Study of Liver Diseases (AASLD
-
Assembly Biosciences Reports Grant Under Nasdaq Listing Rule 5635(c)(4)
11/6/2020
Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced a grant of stock options to a new employee to purchase 6,520 shares of the Company’s common stock with an exercise price of $14.75 per share, the closing price of Assembly’s common stock on November 2, 2020. The stock optio